Le Lézard
Classified in: Health
Subject: AWD

Neurohacker Collective Named to Fastest Growing Companies in San Diego List


CARLSBAD, Calif., Jan. 19, 2021 /PRNewswire/ -- Neurohacker Collective, a Carlsbad company known for its premium brain supplement Qualia Mind has been named to the San Diego Business Journal List of Fastest-Growing Private Companies in San Diego 2020. The Business Journal lists businesses across all industries ranking them by percent of verified revenue growth from 2017 to 2019. Neurohacker Collective earned its rank with a reported 65% increase in annual revenue over the designated time.

Neurohacker Collective has been named to the San Diego Business Journal List of Fastest-Growing Private Companies.

Neurohacker Collective is famous for its cutting-edge science podcast, its rapidly growing biohacking community, and being one of the most innovative supplement companies utilizing complex systems science. The team behind Neurohacker Collective are all pioneers in their field and are committed to ensuring their groundbreaking formulations enable people to perform at their peak. Along with a group of scientists in complex-systems modeling, neurobiology, organic chemistry, and PhD and MD advisors, three highly effective entrepreneurs launched Neurohacker: Jordan Hall, James Schmachtenberger, and Daniel Schmachtenberger. In 2020 the company released Qualia Night for sleep optimization and Qualia Immune for robust immune system support. Currently, the company is developing advanced formulations for mood, pain, skin health, blue-light protection, fitness performance, hormone balancing, and cardiovascular health.

CEO James Schmactenberger said, "This is a great honor to be recognized for our growth this year. We are extremely humbled and grateful for having such an incredible community of supporters. It is for them that we are inspired to innovate every aspect of our business with forward-looking science, high-quality ingredients, and the best customer service."

About Neurohacker Collective
Neurohacker Collective was founded in 2015 with the mission to advance human quality of life by creating best in class well-being products. Neurohacker Collective's products are radically different because they employ a unique methodology to research and development based on complex systems science. This scientific approach focuses on supporting the body's ability to self-regulate. The company began with a focus on cognitive products with the launch of Qualia Mind and has since developed products to support longevity, energy, sleep, and immunity. Learn more about their scientific approach here.

 

SOURCE Neurohacker Collective


These press releases may also interest you

at 18:30
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four...

at 18:16
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 17:56
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget.  The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...

at 17:45
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIREŽ (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...



News published on and distributed by: